SCHEMBL10102722

SCHEMBL10102722

Cn1c(Br)nc([N+](=O)[O-])c1CO

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.36
HTT P42858 5/20 0.36
POLB P06746 1/20 0.36
ATM Q13315 1/20 0.35
KMT2A Q03164 5/20 0.34
ALDH1A1 P00352 4/20 0.34
LMNA P02545 5/20 0.34
THRB P10828 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
RECQL P46063 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MEN1 O00255 1/20 0.33
F2R P25116 1/20 0.33
F2RL3 Q96RI0 1/20 0.33
KDM4E B2RXH2 1/20 0.32
CYP2C19 P33261 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102725 0.84 GAA (0.34) MAPTHTTPOLBKMT2AALDH1A1
SCHEMBL10102740 0.81 ALDH1A1 (0.44) MAPTHTTPOLBATMKMT2A
SCHEMBL10102749 0.79 KMT2A (0.40) MAPTHTTPOLBKMT2AALDH1A1
SCHEMBL10102780 0.78 ALDH1A1 (0.39) MAPTHTTATMKMT2AALDH1A1
SCHEMBL10102723 0.77 ATM (0.33) MAPTATMKMT2AALDH1A1LMNA
SCHEMBL31144987 0.76 MAPT (0.41) MAPTHTTPOLBKMT2AALDH1A1
SCHEMBL10102719 0.76 ATM (0.33) MAPTATMKMT2AALDH1A1LMNA
SCHEMBL16882295 0.76 KMT2A (0.37) MAPTHTTPOLBATMKMT2A
SCHEMBL10108151 0.76 ATM (0.33) MAPTHTTATMKMT2AALDH1A1
SCHEMBL10102776 0.74 ATM (0.32) MAPTATMKMT2ALMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119708057-A Preparation method of N, N' -bis (2-bromo/chloroethyl) diaminophosphonic acid (1-methyl-4-nitro-1H-imidazole-2-cyanomethyl) ester 常州大学 2025-03-28 CN claimed
CN-119708057-A Preparation method of N, N' -bis (2-bromo/chloroethyl) diaminophosphonic acid (1-methyl-4-nitro-1H-imidazole-2-cyanomethyl) ester 常州大学 2025-03-28 CN disclosed
EP-2406262-B1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LTD (NZ) 2016-02-17 EP disclosed
US-20160031877-A1 KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2016-02-04 US disclosed
US-20160031877-A1 KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2016-02-04 US disclosed
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2016-01-07 US disclosed
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2016-01-07 US disclosed
US-9101632-B2 Kinase inhibitors, prodrug forms thereof and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2015-08-11 US disclosed
US-9101632-B2 Kinase inhibitors, prodrug forms thereof and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2015-08-11 US disclosed
US-9073916-B2 Prodrug forms of kinase inhibitors and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2015-07-07 US disclosed
US-9073916-B2 Prodrug forms of kinase inhibitors and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2015-07-07 US disclosed
US-20120202832-A1 KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2012-08-09 US disclosed
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2012-03-29 US disclosed
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY NTRK3, TK1, TNNI3K MAPT 3315/4885HTT 3450/4885POLB 1905/4885
US-20160031877-A1 KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY ERBB2, MAP3K3, ERBB3 MAPT 4568/4885HTT 4724/4885POLB 2226/4885
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY NTRK3, TK1, TNNI3K MAPT 3259/4885HTT 3186/4885POLB 2282/4885
US-20120202832-A1 KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY ERBB2, MAP3K3, MAP3K19 MAPT 4501/4885HTT 4698/4885POLB 2165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.